MUDr. Ivanna Boichuk
Department of Internal Medicine, Hematology and Oncology
e‑mail: |
---|
Total number of publications: 8
2024
-
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Blood Cancer Journal, year: 2024, volume: 14, edition: 1, DOI
-
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
European Journal of Haematology, year: 2024, DOI
2023
-
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
Annals of Hematology, year: 2023, volume: 102, edition: 6, DOI
2022
-
Léčba nemocnění asociovaného s imunoglobulinem IgG4
Vnitřní lékařství, year: 2022, volume: 68, edition: 6, DOI
-
Pozvolný vzestup bilirubinu v průběhu léčby mnohočetného myelomu lenalidomidem, bortezomibem a dexametazonem (demaskování dříve nediagnostikovaného Gilbertova syndromu) a vymizení nekrobiotického xantogranulomu po dosažení kompletní remise myelomu
Klin onkol, year: 2022, volume: 35(4), DOI
2021
-
Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia
British journal of haematology, year: 2021, volume: 195, edition: 1, DOI
-
Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant
Neoplasma, year: 2021, volume: 68, edition: 3, DOI
2019
-
Bortezomib and Th alidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
Klinická onkologie, year: 2019, volume: 32, edition: 6